Focus: Larimar Therapeutics is a small-molecule focused biotech company headquartered in Bala Cynwyd, PA, specializing in neurology with an early-stage pipeline targeting rare neurological diseases like Friedreich Ataxia. The company operates as a pre-revenue biotech with modest headcount and is actively expanding R&D and commercial capabilities.
Profile data last refreshed 23m ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Larimar is a mission-driven early-stage bet for scientists and clinicians comfortable with execution risk in exchange for deep pipeline influence and rare-disease impact.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Larimar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Larimar Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September - Investing.com UK
Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September Investing.com UK
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? Stocktwits
Larimar Therapeutics (NasdaqGM:LRMR) Stock Forecast & Analyst Predictions - Simply Wall Street
Larimar Therapeutics (NasdaqGM:LRMR) Stock Forecast & Analyst Predictions Simply Wall Street
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside - TradingView
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside TradingView
Larimar Therapeutics Appoints John B. Harlow Jr. as President and COO - Kalkine Media
Larimar Therapeutics Appoints John B. Harlow Jr. as President and COO Kalkine Media
John Harlow Joins Larimar Therapeutics as President and Chief Operating Officer - BioBuzz
John Harlow Joins Larimar Therapeutics as President and Chief Operating Officer BioBuzz
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles